공시 • Mar 27
MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026 MARX Biotech Co., Ltd., Annual General Meeting, Jun 24, 2026. Location: 13 floor no,659, pan s. rd., jhonghe district, new taipei city Taiwan New Risk • Mar 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$3.01b market cap, or US$95.8m). New Risk • Jan 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$368m free cash flow). Share price has been highly volatile over the past 3 months (8.5% average weekly change). Earnings have declined by 91% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$2.21b market cap, or US$69.8m). New Risk • Jul 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$326m free cash flow). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (NT$2.56b market cap, or US$86.9m). Reported Earnings • Apr 13
Full year 2024 earnings released: NT$0.19 loss per share (vs NT$0.03 loss in FY 2023) Full year 2024 results: NT$0.19 loss per share (further deteriorated from NT$0.03 loss in FY 2023). Revenue: NT$618.2m (up 113% from FY 2023). Net loss: NT$96.8m (loss widened NT$83.9m from FY 2023). New Risk • Apr 07
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.05b (US$92.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$3.05b market cap, or US$92.1m). 공시 • Mar 28
MARX Biotech Co., Ltd., Annual General Meeting, Jun 16, 2025 MARX Biotech Co., Ltd., Annual General Meeting, Jun 16, 2025, at 09:30 Taipei Standard Time. Location: 13 floor no,659, pan nan rd., jhonghe district, new taipei city Taiwan New Risk • Mar 03
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$74m free cash flow). Share price has been highly volatile over the past 3 months (8.0% average weekly change). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). New Risk • Jan 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$74m free cash flow). Minor Risk Share price has been volatile over the past 3 months (7.5% average weekly change). New Risk • Jan 09
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.28b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$74m free cash flow). Minor Risk Market cap is less than US$100m (NT$3.28b market cap, or US$99.6m). 공시 • Mar 16
MARX Biotech Co., Ltd., Annual General Meeting, May 30, 2024 MARX Biotech Co., Ltd., Annual General Meeting, May 30, 2024.